Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Complete title: TACL 2014-001: A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma.

Research Study Number TACL 2014-001
 
Principal Investigator Todd Cooper
 
Phase I

Research Study Description

This is a phase I study of temsirolimus (Torisel) combined with dexamethasone, cyclophosphamide and etoposide in patients with relapsed acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) or peripheral T-cell lymphoma (PTL).

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number TACL 2014-001
 
Contact Todd Cooper
 
Telephone 206/987-2106
 
E-mail
 

Keywords: Leukemia, Acute Lymphoblastic (ALL); Leukemia; Lymphoma; Lymphoproliferative Disorders; Pediatric Cancers, Miscellaneous; Lymphoma, Non-Hodgkin (NHL); Neoplasms; Leukemia, Lymphoid; Immunoproliferative Disorders; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Immune System Diseases; Lymphoma, Lymphoblastic (LBL)

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials